Published in PLoS Pathog on May 12, 2011
Driving forces of proteasome-catalyzed peptide splicing in yeast and humans. Mol Cell Proteomics (2012) 0.89
Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome. J Acquir Immune Defic Syndr (2015) 0.80
The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection. Retrovirology (2015) 0.79
Mechanisms of HIV protein degradation into epitopes: implications for vaccine design. Viruses (2014) 0.79
Acute phase CD8+ T lymphocytes against alternate reading frame epitopes select for rapid viral escape during SIV infection. PLoS One (2013) 0.78
Viral infection causes a shift in the self peptide repertoire presented by human MHC class I molecules. Proteomics Clin Appl (2015) 0.76
Presentation of Cryptic Peptides by MHC Class I Is Enhanced by Inflammatory Stimuli. J Immunol (2016) 0.75
Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M. PLoS One (2013) 0.75
Immunoproteasomes edit tumors, which then escapes immune recognition. Eur J Immunol (2015) 0.75
Two ribosome recruitment sites direct multiple translation events within HIV1 Gag open reading frame. Nucleic Acids Res (2017) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature (2000) 7.10
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 6.33
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Architecture and secondary structure of an entire HIV-1 RNA genome. Nature (2009) 6.12
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 5.18
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta (2005) 3.36
Antigen processing by the proteasome. Nat Rev Mol Cell Biol (2001) 2.93
Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med (2001) 2.27
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol (2004) 2.12
26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J (2001) 2.09
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03
DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood (2003) 1.89
Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med (1996) 1.86
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Portable flanking sequences modulate CTL epitope processing. J Clin Invest (2007) 1.72
Constitutive display of cryptic translation products by MHC class I molecules. Science (2003) 1.67
Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood (2006) 1.58
A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity (1996) 1.58
ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat Immunol (2001) 1.56
The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med (1995) 1.56
Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames. J Exp Med (2004) 1.48
AIDS virus specific CD8+ T lymphocytes against an immunodominant cryptic epitope select for viral escape. J Exp Med (2007) 1.47
Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames. J Exp Med (1996) 1.39
Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol (2006) 1.36
CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J Exp Med (2010) 1.27
Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J Biol Chem (2001) 1.26
ABC proteins in antigen translocation and viral inhibition. Nat Chem Biol (2010) 1.22
CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol (2005) 1.21
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol (2004) 1.21
Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J Exp Med (2010) 1.19
Alternative translational products and cryptic T cell epitopes: expecting the unexpected. J Immunol (2006) 1.14
HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol (2008) 1.13
HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol (2004) 1.13
HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int Immunol (2003) 1.13
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. J Exp Med (1999) 1.08
The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med (2009) 1.07
The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One (2010) 1.04
Precise identification of a human immunodeficiency virus type 1 antigen processing mutant. J Virol (2006) 1.02
An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus. J Immunol (1998) 0.99
Robust, vaccine-induced CD8(+) T lymphocyte response against an out-of-frame epitope. J Immunol (2009) 0.93
Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses. Clin Vaccine Immunol (2009) 0.92
The effect of the interferon-gamma-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur J Immunol (2002) 0.92
+1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin 10. J Exp Med (2002) 0.88
Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses. J Virol (2010) 0.82
Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption. J Acquir Immune Defic Syndr (2010) 0.81
Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct. AIDS (2009) 0.80
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature (2011) 9.30
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol (2010) 4.25
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS (2006) 3.82
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature (2005) 3.53
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med (2003) 3.32
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep (2003) 3.29
Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol (2006) 3.26
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
A patient with HIV-1 superinfection. N Engl J Med (2002) 2.93
SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology (2012) 2.92
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis (2010) 2.90
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem (2003) 2.82
Macrophage plasticity in experimental atherosclerosis. PLoS One (2010) 2.75
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol (2010) 2.64
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity (2010) 2.52
Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One (2007) 2.47
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol (2007) 2.43
Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity (2007) 2.42
Accelerated immune senescence and HIV-1 infection. Exp Gerontol (2007) 2.41
Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. J Virol (2009) 2.33
Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood (2009) 2.33
Innate sensing of HIV-infected cells. PLoS Pathog (2011) 2.22
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med (2004) 2.08
The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes (2008) 2.04
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03
The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe (2012) 2.03
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis (2006) 2.02
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res (2009) 2.00
CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes (2007) 1.98
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol (2004) 1.93
Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J Virol (2005) 1.92
Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse. Immunity (2006) 1.90
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood (2003) 1.89
PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS (2007) 1.88
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med (2010) 1.86
Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest (2003) 1.85
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Evidence of premature immune aging in patients thymectomized during early childhood. J Clin Invest (2009) 1.81
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev (2009) 1.76
Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation. J Virol (2005) 1.74
Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 1.74
Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog (2010) 1.73
ZAP-70 kinase regulates HIV cell-to-cell spread and virological synapse formation. EMBO J (2007) 1.68
Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol (2008) 1.68
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS (2010) 1.65
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS (2003) 1.64
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med (2013) 1.62
HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity (2002) 1.62
HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med (2004) 1.60